Tesamorelin HA - 10MG

Tesamorelin clinical summary

Tesamorelin is a synthetic growth hormone–releasing hormone (GHRH) analogue approved for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. It stimulates pituitary GH secretion, increasing IGF-I and driving downstream metabolic effects.^[1][2][3]

Growth hormone release & IGF-I elevation

Daily s.c. tesamorelin (2 mg) significantly raises circulating GH and IGF-I; IGF-I increases by ~81% over 26 weeks in HIV-infected patients, with effects maintained during therapy.^[4][5][6]

Visceral fat reduction

Tesamorelin selectively reduces visceral adipose tissue (VAT) by ~15–20% over 6–12 months in HIV-associated lipodystrophy, with minimal impact on subcutaneous fat; VAT reduction is sustained while on treatment and reverses after discontinuation. Odds of achieving VAT < 140 cm² are ~4× higher vs placebo; efficacy is similar on integrase inhibitor–based ART.^{[5][4][2][6][7][8][3][9][10]}

Lean muscle & body composition

Improvements in trunk fat, waist circumference, and waist–hip ratio occur without significant loss of limb/subcutaneous fat. Some studies show favorable shifts in trunk-to-appendicular fat ratio and hepatic fat fraction.^{[5][2][3][10]}

Metabolic & lipid profile

VAT reduction correlates with lower triglycerides (~50 mg/dL at 26 weeks), improved total-cholesterol/HDL ratio, and higher adiponectin, with neutral effects on glucose parameters/HbA1c in trials.^[11][4][6]

Cardiovascular health

Tesamorelin reduces carotid intima-media thickness (cIMT) and C-reactive protein in settings of reduced GH secretion and in HIV-infected patients, suggesting CV risk benefit.^[12][4]

Physical performance & well-being

Trials consistently report improvements in body-image distress, belly appearance, and overall well-being; lean mass gains and VAT loss may contribute to functional benefits.^[5][2][3]

Safety & tolerability

Generally well tolerated with AE rates comparable to placebo; common events include mild injection-site reactions, arthralgia, headache, and peripheral edema. Long-term studies show no major glucose liability or serious AEs attributable to treatment.^[4][2][6][3]

Dosage

• Approved dose: 2 mg s.c. once daily for HIV-associated lipodystrophy.^[1][8]
• Other formulations: Lower doses (1.28–1.4 mg) used in some products with similar VAT reduction reported.^[1][8]

Summary: Tesamorelin (10 mg) is a GHRH analogue with strong evidence for selective VAT reduction, improved lipid/metabolic profiles, favorable body composition changes, potential cardiovascular benefits, and a well-established safety profile in HIV-associated lipodystrophy and in obese adults with reduced GH secretion.^{[12][1][9][11][10][5][4][2][6][7][8][3]}

References

1. EGRIFTA SV. Food and Drug Administration. Updated 2024-12-12.
2. Dhillon S. Drugs. 2011;71(8):1071-91.
3. Spooner LM, Olin JL. Ann Pharmacother. 2012;46(2):240-7.
4. Falutz J, Allas S, Blot K, et al. NEJM. 2007;357:2359-70.
5. Falutz J, Potvin D, Mamputu JC, et al. JAIDS. 2010;53(3):311-22.
6. Falutz J, Allas S, Mamputu JC, et al. AIDS. 2008;22(14):1719-28.
7. Falutz J, Allas S, Blot K, et al. NEJM. 2007;357:2359-70.
8. EGRIFTA WR. FDA. Updated 2025-03-31.
9. Mangili A, Falutz J, Mamputu JC, et al. PLOS One. 2015;10(10):e0140358.
10. Russo SC, Ockene MW, Arpante AK, et al. AIDS. 2024;38(12):1758-1764.
11. Stanley TL, Falutz J, Marsolais C, et al. Clin Infect Dis. 2012;54(11):1642-51.
12. Makimura H, Feldpausch MN, Rope AM, et al. J Clin Endocrinol Metab. 2012;97(12):4769-79.

All COA’s avail upon request by email info@truformlabs.com.

Storage & Handling (Research Use)

• Lyophilized (dry) peptide: Store sealed at −20 °C (long-term). Short-term storage up to 2–3 weeks at 2–8 °C is acceptable.
• After reconstitution: Store at 2–8 °C and use within 7 days, or aliquot into sterile vials and freeze at −20 °C for up to 3 months.
• Light & moisture: Protect from light; keep container tightly closed to avoid moisture uptake.
• Freeze–thaw: Avoid repeated freeze–thaw cycles (use aliquots).
• Solvent compatibility: Choose sterile solvent compatible with your protocol; filter-sterilize if required by your procedures.
• Labeling: Clearly label aliquots with concentration, solvent, and date of preparation.

Storage guidance is general for research peptides and may be adjusted per your lab SOP.